Finally, we found that that regulatory T-cells were relatively enriched in combination immunotherapy responders compared to anti-PD-1 monotherapy responders (Figure 3d), and this difference could not be attributed to the variation in tumor MHC expression, nor did it correlate with the relative myeloid fraction. This evidence concerns the gene HLA-C and neoplasm.